Urinary excretion of apo(a) fragments: Role in apo(a) catabolism

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 8, 1996, Pages 905-911

  Kostner, Karam M ^a   Maurer, Gerald ^a   Huber, Kurt ^a   Stefenelli, Thomas ^a   Dieplinger, Hans ^b   Steyrer, Ernst ^c   Kostner, Gert M ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

^c UNIVERSITY OF GRAZ   (Austria)

Author keywords

kidney; kringle IV; urinary excretion

Indexed keywords

APOLIPOPROTEIN A; CREATININE; LIPOPROTEIN A;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNOBLOTTING; KRINGLE DOMAIN; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN URINE LEVEL; URINARY EXCRETION;

EID: 0029838377     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.8.905     Document Type: Article

References (39)

1. Berg K, Dahlen G, Frick MH. Lp(a) lipoprotein and pre-β1-lipoprotein in patients with coronary heart disease. Clin Genet. 1974;6:230-235.
2. Kostner GM, Avogaro P, Cazzolato G, Marth E, Bittolobon G. Lipoprotein Lp(a) and the risk for myocardial infarction. Atherosclerosis. 1981;38:51-61.
3. Armstrong VW, Cremer P, Eberle E, Manke A, Schulze F, Wieland H, Kreuzer H, Seidel D. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Atherosclerosis. 1986;62:249-257.
4. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyana M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis. 1986;59:199-204.
5. Cushing GL, Gaubatz JW, Nava ML, Burdick BJ, Bocan TMA, Guyton JR, Weilbaecher D, DeBakey ME, Lawrie GM, Morrisett JD. Quantitation and localization of apolipoprotein(a) and B in coronary artery bypass vein grafts resected at re-operation. Arteriosclerosis. 1989;9:593-603.
6. Maher VMG, Brown BG. Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol. 1995;6:229-235.
7. Gaubatz JW, Ghanem KI, Guevara J, Nava ML, Patsch W, Morisett DJ. Polymorphic forms of human apolipoprotein(a): inheritance and relationship of their molecular weights to plasma levels of lipoprotein(a). J Lipid Res. 1980;31:603-613.
8. McLean JW, Tomlinson JE, Kuang WJ, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature. 1987;330:132-137.
9. Marcovina SM, Albers JJ, Jacobs DR Jr, Perkins LL, Lewis CE, Howard BV, Savage P. Lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in Caucasians and African Americans. Arterioscler Thromb. 1993;13:1037-1045.
10. Steyrer E, Durovic S, Frank S, Gießauf W, Burger A, Dieplinger H, Zechner R, Kostner GM. The role of lecithin:cholesterol acyltransferase for lipoprotein(a) assembly: structural integrity of low density lipoproteins is a prerequisite for Lp(a) formation in human plasma. J Clin Invest. 1994;94:2330-2340.
11. Sandholzer C, Hallman DM, Saha N, Sigurdsson G, Lackner C, Csaszar A, Boerwinkle E, Utermann G. Effects of the apolipoprotein(a) size polymorphism on the lipoprotein(a) concentration in 7 ethnic groups. Hum Genet. 1991;86:607-614.
12. Gaw A, Boerwinkle E, Cohen JC, Hobbs HH. Comparative analysis of the apo(a) gene, apo(a) glycoprotein, and plasma concentrations of Lp(a) in three ethnic groups. J Clin Invest. 1994;93:2526-2534.
13. Austin MA, Sandholzer C, Selby JV, Newman B, Krauss RM, Utermann G. Lipoprotein(a) in women twins: heritability and relationship to apolipoprotein phenotypes. Am J Hum Genet. 1992;51:829-840.
14. Krempler F, Kostner GM, Bolzano K, Sandhofer F. Lipoprotein(a) is not a metabolic product of other lipoproteins containing apolipoproteinB. Biochim Biophys Acta. 1979;575:63-70.
15. Krempler F, Kostner GM, Bolzano K. Turnover of lipoprotein(a) in man. J Clin Invest. 1980;65:1483-1490.
16. White AL, Lanford RE. Biosynthesis and metabolism of lipoprotein(a). Curr Opin Lipidol. 1995;6:75-80.
17. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG-CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation. 1989;80:1313-1319.
18. Oida K, Takai H, Maeda H, Takahashi S, Shimada A, Suzuki J, Tamai T, Nakai T, Miyabo S. Apolipoprotein (a) is present in urine and its excretion is decreased in patients with renal failure. Clin Chem. 1992;38:2244-2248.
19. Durovic S, März W, Frank S, Scharnagl H, Baumstark MW, Zechner R, Kostner GM. Decreased binding of apolipoprotein(a) to familial defective apolipoprotein B-100 (Arg 3500 Gln), J Biol Chem. 1994;269:30320-30325.
20. Frank S, Krasznai K, Durovic S, Lobentanz E-M, Dieplinger H, Wagner E, Zatloukal K, Gotten M, Utermann G, Kostner GM, Zechner R. High level expression of various apolipoprotein(a) isoforms by 'transferrinfection': the role of kringle-IV sequences in the extracellular association with low density lipoprotein. Biochemistry. 1994;33:12329-12339.
21. Kostner GM, Grillhofer H. The interaction of Lp(a) with normal and LDL-receptor deficient human skin fibroblasts. Chem Phys Lipids. 1994;67/68:153-159.
22. Armstrong VM, Valli AK, Seidel D. Isolation, characterisation and uptake in human fibroblasts of an apo-a-free lipoprotein obtained on reduction of lipoprotein a. J Lipid Res. 1985;26:1314-1323.
23. Frank S, Durovic S, Kostner GM. Structural requirements of apo-a for the Lp(a) assembly. Biochem J. 1994;304:27-30.
24. Dieplinger HD, Gruber G, Krasznai K, Reschauer S, Seidel C, Burns G, Müller HJ, Csaszar A, Vogel W, Robenek H, Utermann G. Kringle 4 of human apolipoprotein (a) shares a linear antigenic site with human catalase. J Lipid Res. 1995;36:813-822.
25. Huby T, Doucet C, Dieplinger H, Chapman J, Thillet J. Structural domains of apolipoprotein(a) and its interaction with apolipoprotein B-100 in the lipoprotein(a) particle. Biochemistry. 1994;33:3335-3341.
26. Kraft HG, Lingenhel A, Bader G, Kostner GM, Utermann G. The relative electrophoretic mobility of apo(a) isoforms depends on the gel system: proposal of a nomenclature for apo(a) phenotypes. Atherosclerosis. In press.
27. Trieu VN, McConathy WJ. A two-step model for lipoprotein(a) formation. J Biol Chem. 1995;270:15471-15474.
28. Koschinsky ML, Cote GP, Gabel B, van der Hoek YY. Identification of the cysteine residue in apolipoprotein B-100. J Biol Chem. 1993;268:19819-19825.
29. Brunner C, Kraft H-G, Utermann G, Müller H-J. Cys 4057 of apolipoprotein(a) is essential for lipoprotein(a) assembly. Proc Natl Acad Sci U S A. 1993;90:11643-11647.
30. Steyrer E, Kostner GM. The interaction of lipoprotein Lp(a) with the B/E receptor. J Lipid Res. 1990;31:1247-1253.
31. Rader DJ, Mann WA, Cain W, Kraft HG, Usher D, Zech LA, Hoeg JM, Davignon J, Lupien P, Grossmann M, Wilson JM, Brewer HB. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J Clin Invest. 1995;95:1403-1408.
32. Rader DJ, Cain W, Zech LA, Usher D, Brewer HB Jr. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein(a) isoform is determined by the rate of lipoprotein(a) production. J Clin Invest. 1993;91:443-447.
33. Rader DJ, Cain W, Ikewaki K, Talley G, Zech LA, Usher D, Brewer HB Jr. The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J Clin Invest. 1994;93:2758-2763.
34. Kronenberg F, Utermann G, Dieplinger H. Lipoprotein(a) in renal disease. Am J Kidney Dis. In press.
35. Kronenberg F, König P, Lhotta K, Öfner D, Sandholzer C, Margreiter R, Dosch E, Utermann G, Dieplinger H. Apolipoprotein(a) phenotype-associated decrease in lipoprotein(a) plasma concentrations after renal transplantation. Arterioscler Thromb. 1994;14:1399-1404.
36. Kostner GM. The physiological role of Lp(a). In: Day CC, Levy RS, eds. Low Density Lipoproteins. New York/London: Plenum Press; 1976:229-269.
37. Gries A, Nimpf J, Nimpf M, Wurm H, Kostner GM. Free and apoB associated Lp(a) specific protein in human serum. Clin Chim Acta. 1987;164:93-100.
38. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 1994;79:315-328.
39. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell. 1994;79:185-188.